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abstract As a background for this Thesis, the author presents the definition 
and implementation of a healthcare organization system for Pulmonary 
Hypertension (PH) in Portugal and the development of a dedicated 
information technology system for PH management and clinical research 
(PAHTool™), in both cases he was actively involved.  
Taking advantage of the clinical research potentialities created by 
the referral centers’ network that was implemented and the availability of 
PAHTool™, the author and his colleagues conducted a series of studies 
to characterize the Portuguese PH population in terms of epidemiology, 
clinical characteristics, treatment options, outcomes, and Quality of Life 
and Disability impairment. All these studies have been published or 
accepted for publication by peer-reviewed scientific journals.  
 
“Pulmonary Hypertension in Portugal: 1st Data from a Nationwide 
Registry” was a prospective, observational, multicenter registry from five 
PH centers in Portugal. Predominance of females (65.2%), relatively 
young patients (43.416.4 years) and idiopathic pulmonary arterial 
hypertension (IPAH) etiology (37.0%) were the most relevant findings in 
the pulmonary arterial hypertension (PAH) group. Most patients were 
treated with single (50%), double (28%) or triple (9%) combination 
therapy. The 1-year survival estimate was 93.5% and 93.9% for the PAH 
and chronic thromboembolic pulmonary hypertension (CTEPH) groups, 
respectively. The main findings of this registry were in line with that of 
other international registries. 
 
“Pulmonary Hypertension: Real-world Data from a Portuguese 
Expert Referral Center” was a retrospective analysis of a cohort of 101 
patients with pre-capillary PH (pcPH) referenced to an expert tertiary care 
referral center in northern Portugal, from 2002 to 2013. This study 
provided long-term (3.82.7 years) real-world data of a predominantly 
incident population (80.2%), where the most relevant demographic 
findings were the female gender predominance (66.3%) and the relatively 
young age of the population (49.619.6 years). The high number (>60%) 
of patients in advanced stage of the disease at presentation suggested 
delayed diagnosis and highlighted the need to increase PH awareness 
among clinicians and explains why most patients were treated with 
combination therapy (53.2%). There was a significant improvement of 
World Health Organization functional class (WHO FC) (p<0.003), 6-
minutes walking distance (6MWD) (p=0.003), mean pulmonary artery 
pressure (mPAP) (p=0.002), and pulmonary vascular resistance (PVR) 
(p=0.008), without significant changes in mean right atrial pressure 
(mRAP) and cardiac index (CI). The cumulative probability of survival at 
 x 
 
  
1-, 3- and 5-years for the total cohort (respectively 86.6%, 76.7%, 64.1%), 
PAH (91.8%, 80.3%, 66.2%) and CTEPH (81.5%, 75.3%, 67.3%) and the 
substantial proportion of patients with idiopathic/heritable pulmonary 
arterial hypertension (I/HPAH) treated with triple combination therapy 
(61.1%) highlight the access to modern targeted therapies and 
compliance with international guidelines.  
 
“Long-term Survival in Pulmonary Arterial Hypertension and 
Chronic Thromboembolic Pulmonary Hypertension: Insights from a 
Referral Center in Portugal” intended to assess the long-term survival of 
a cohort of 142 patients followed up in a Portuguese referral center. This 
study showed that comparing the cohorts of patients treated in two 
periods, 2011-2016 and 2005-2010, a trend toward improved survival at 
5 years was found for connective tissue disease-associated pulmonary 
arterial hypertension (CTD-PAH) (67% vs 33%) and CTEPH (84% vs 
77%), but not for patients with I/HPAH (75% vs 84%). Earlier diagnosis, 
increasing use of parenteral prostanoids, and improvement of surgical 
treatments (pulmonary endarterectomy and lung transplantation) access 
were deemed necessary to further improve PAH and CTEPH patient’s 
outcomes. 
 
“Portuguese Validation of the Cambridge Pulmonary Hypertension 
Outcome Review (CAMPHOR) Questionnaire” was a study aiming to 
translate and validate the CAMPHOR questionnaire for the European 
Portuguese-speaking population. Good internal consistency and 
reproducibility, as well as excellent convergent reliability and group 
validity was found for the Portuguese version of the CAMPHOR 
questionnaire. 
 
In “Health-Related Quality of Life in Pulmonary Hypertension and 
Its Clinical Correlates: A Cross-Sectional Study” it was demonstrated that 
HRQoL, measured by two different patient-reported outcomes measures 
(PROMs) (CAMPHOR, a PH-specific questionnaire, and Nottingham 
Health Profile, a general one), is impaired in Portuguese patients with 
PAH and other forms of pcPH, particularly in patients with increased 
disease severity. WHO FC, 6MWD, and Borg dyspnea index were highly 
correlated with health-related quality of life (HRQoL), measured by both 
instruments and quality of life (QoL), measured by CAMPHOR.   
 
In “Disability and Its Clinical Correlates in Pulmonary Hypertension 
Measured Through the World Health Organization Disability Assessment 
Schedule II (WHODAS 2.0): a prospective, observational study” the 
studied PH population showed mild disability, with higher degree of 
disability in the domains of Mobility and Life activities. WHODAS 2.0 
scores at baseline were robustly predictive of 6MWD and WHO functional 
class evolution. This study was the first one to assess disability in PH 
patients, using WHODAS 2.0. 
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pulmonar, Qualidade de Vida, Qualidade de Vida Relacionada com 
a Saúde e Incapacidade funcional 
  
resumo Como enquadramento desta Tese, o autor apresenta a 
definição e implementação de um sistema de organização de 
cuidados de saúde para a hipertensão pulmonar (HP) em Portugal e 
o desenvolvimento de um sistema de informação dedicado para a 
gestão e investigação clínica da hipertensão pulmonar (PAHTool™), 
em ambos os projetos o autor teve participação ativa. 
Aproveitando as potencialidades de investigação clínica 
criadas pela rede de centros de referência implementada e pela 
disponibilidade do PAHTool™, o autor e os seus colegas realizaram 
uma série de estudos para caracterizar a população de doentes com 
HP em Portugal, em termos de epidemiologia, características 
clínicas, opções de tratamento, resultados clínicos e repercussões na 
qualidade de vida e capacidade funcional. Todos os estudos 
realizados foram publicados ou aceites para publicação em revistas 
científicas com revisão por pares.    
 
“Hipertensão Pulmonar em Portugal: 1os Dados de um Registo 
Nacional”, foi um registo prospetivo, observacional e multicêntrico, de 
cinco centros em Portugal. A predominância do género feminino 
(65.2%), de doentes relativamente jovens (43.416.4 anos) e da 
etiologia hipertensão arterial pulmonar idiopática (37,0%) foram os 
resultados mais relevantes do grupo com hipertensão arterial 
pulmonar. A maioria dos doentes foi tratada com um fármaco 
vasodilatador pulmonar específico (50%); 28% dos doentes foram 
tratados com combinação de dois destes fármacos e 9% com a 
combinação de três. A estimativa de sobrevivência a 1 ano foi de 
93,5% e 93.9% para os grupos hipertensão arterial pulmonar e 
hipertensão pulmonar tromboembólica crónica, respetivamente. Os 
resultados principais deste primeiro registo português foram 
semelhantes aos de outros registos internacionais. 
 
No estudo “Hipertensão Pulmonar: Dados do Mundo Real de 
um Centro Especializado de Referência Português”, fez-se uma 
análise retrospetiva de 101 doentes com HP pré-capilar, 
referenciados para um centro de referência de cuidados terciários no 
norte de Portugal, durante os anos de 2002 a 2013. Este estudo 
forneceu dados de vida-real a longo prazo (3,8±2,7 anos), de uma 
população predominantemente incidente (80,2%), onde os resultados 
demográficos mais relevantes foram a predominância do género 
feminino (66,3%) e de doentes relativamente jovens (49,6±19,6 
anos). A apresentação da maioria dos doentes (>60%) em risco 
intermédio ou alto de mortalidade sugere um atraso no diagnóstico 
da doença e aconselha a uma maior divulgação desta entidade entre 
os profissionais de saúde e explica a utilização de tratamento 
combinado com várias drogas na maioria da população (53,2%). 
 xii 
Houve uma melhoria significativa da classe funcional da Organização 
Mundial de Saúde (p<0,003), da distância percorrida no teste dos 6 
minutos de marcha (p=0,003), da pressão média da artéria pulmonar 
(p=0,002) e da resistência vascular pulmonar (p=0,008), sem 
alterações significativas do valor da pressão média da aurícula direita 
e do índice cardíaco. A probabilidade cumulativa de sobrevivência 
aos 1, 3 e 5 anos foi de respetivamente 86,6%, 76,7% e 64,1% para 
a coorte total, 91,8%, 80,3% e 66,2% para o grupo hipertensão 
arterial pulmonar, e 81,5%, 75,3% e 67,3% para o grupo hipertensão 
pulmonar tromboembólica crónica. A elevada percentagem de 
doentes com hipertensão arterial pulmonar idiopática/hereditária 
tratados com terapêutica combinada tripla (61,1%) reflete a facilidade 
de acesso às novas terapêuticas e o cumprimento das normas de 
tratamento aconselhadas pelas recomendações internacionais.  
 
O estudo “Sobrevivência a Longo Prazo na Hipertensão 
Arterial Pulmonar e na Hipertensão Pulmonar Tromboembólica 
Crónica: Dados de um Centro de Referência em Portugal” pretendeu 
avaliar a sobrevivência a longo prazo de uma coorte de 142 doentes 
seguidos num centro de referência português. Comparando os 
doentes tratados no período de 2011-2016 versus o período de 2005-
2010, verificou-se uma melhoria da sobrevivência a 5 anos para os 
doentes com hipertensão arterial pulmonar associada a doença do 
tecido conjuntivo (67% vs 33%) e da hipertensão pulmonar 
tromboembólica crónica (84% vs 77%), mas não para os doentes com 
hipertensão arterial pulmonar idiopática ou hereditária (75% vs 84%). 
O diagnóstico precoce, o aumento do uso de prostanóides por via 
parentérica e a melhoria do acesso aos tratamentos cirúrgicos da 
hipertensão pulmonar (endarterectomia pulmonar e transplante 
pulmonar) foram considerados necessários para atingir melhorias 
adicionais no prognóstico dos doentes com hipertensão arterial 
pulmonar e hipertensão pulmonar tromboembólica crónica. 
 
O artigo “Tradução e Validação para Português do Cambridge 
Pulmonary Hypertension Outcome Review (CAMPHOR)” descreve o 
processo de tradução e validação do questionário CAMPHOR para a 
população portuguesa com hipertensão pulmonar. Este estudo 
demonstrou a boa consistência interna e reprodutibilidade, bem como 
a excelente fiabilidade convergente e a validade de grupo da versão 
portuguesa deste questionário. 
 
Em “Qualidade de Vida Relacionada com a Saúde na 
Hipertensão Pulmonar e as suas Correlações Clínicas: Estudo 
Transversal” demonstrou-se que a qualidade de vida relacionada com 
a saúde (HRQoL), medida por dois instrumentos (o CAMPHOR, um 
questionário específico para a hipertensão pulmonar e o Nottingham 
Health Profile, um questionário generalista), está comprometida na 
população portuguesa com hipertensão arterial pulmonar e outras 
formas de hipertensão pulmonar pré-capilar, particularmente nos 
doentes mais graves. A classe funcional da WHO, a distância 
percorrida no teste dos 6 minutos de marcha, a dispneia e o índice de 
Borg estiveram altamente correlacionados com o resultado da 
avaliação da HRQoL, medida por ambos os instrumentos e com a da 
qualidade de vida (QoL), avaliada pelo CAMPHOR.  
 
Em “Incapacidade e as suas Correlações Clínicas na 
Hipertensão Pulmonar Medida Através do World Health Organization 
Disability Assessment Schedule II (WHODAS 2.0): um Estudo 
Observacional, Prospetivo” verificou-se que a população estudada 
apresentava incapacidade ligeira, com maior grau de incapacidade 
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nos domínios da Mobilidade e Atividades da vida diária. A pontuação 
do WHODAS 2.0 no início do estudo foi um preditor forte da evolução 
da classe funcional da WHO e da distância percorrida no teste dos 6 
minutos de marcha. Este trabalho constituiu a primeira publicação da 
aplicação do questionário WHODAS 2.0 a doentes com hipertensão 
pulmonar. 
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1. CHAPTER I – Introduction and Thesis 
Structure 
 
 
 2 
  
 
 3 
 
1.1. Introduction 
 
1.1.1. Pulmonary Hypertension 
 
Since the autopsy observation of the first case of “pulmonary vascular sclerosis” 
by Romberg in 1891,1 a lot of “small steps” were taken to reach our current knowledge 
about pulmonary hypertension (PH). 
One of the most important steps, very well emphasized by Alfred Fishman,2 was 
the introduction of right heart catheterization (RHC), between 1940–50, leading this 
author to consider two distinct “eras” in PH research: before and after the introduction of 
hemodynamic studies. This pioneering statement is still valid nowadays, as RHC 
remains the gold standard for PH definition, classification and follow-up assessment.3–5 
Another important step was the launch of periodic World Symposia on PH 
supported by the World Health Organization (WHO), in 1973, following the epidemy of 
pulmonary hypertension (PH) in Austria, Germany, and Switzerland caused by aminorex, 
an appetite suppressant drug, in the sixties and seventies of the XXth Century.6 A clinical 
classification of PH, based in five groups, was proposed for the first time to the second 
WHO symposium on PH, in 1998.7 Since then, these meetings were both the place for 
analysis and discussion of evidence published in between them (after meticulous work 
and discussion between the members of the different working groups) and the source of 
guidelines and recommendations for the following years.8–10 The most recent PH World 
Symposium took place in 2018, in Nice, France, and the PH community is waiting for the 
publication of the respective proceedings and updated guidelines.  
In the last fifty years, the intense basic research on PH lead to a better 
understanding of its pathobiology and genetics. At the same time, continued 
epidemiological and clinical research, as well as the discovery of new drugs and different 
strategies to use them, brought great improvements in the clinical management of PAH 
patients.11–15 Such improvements lead, ultimately, to a complete transformation in the 
various facets of patients’ lives, including functionality, prognosis, survival, and quality of 
life (QoL).16,17 However, despite these tremendous progresses PAH patients prognosis 
maintains unacceptable bad and we are yet far from getting a cure for this devastating 
group of diseases.18   
Today, as can be seen in table 1, we know that PH is a common complication of 
frequent diseases such as left heart (group 2) and lung diseases (group 3)—the most 
frequent forms of PH—or it can present as an isolated form with a genetic background 
component (heritable) or not (most forms of idiopathic); it can also be induced by some 
drugs (e.g. aminorex, fenfluramine derivatives, benfluorex, and selective serotonin 
reuptake inhibitors) and toxins or associated with other diseases or risk factors 
(connective tissue disorders, HIV infection, liver diseases with portal hypertension and 
congenital heart diseases). These last forms are designated as Pulmonary Arterial 
Hypertension (PAH or group 1) and together with Chronic Thromboembolic Pulmonary 
Hypertension (CTEPH or group 4) are the “core” of attention of the scientific community 
and the only forms of PH with indication for treatment with specific pulmonary 
vasodilators drugs.8,10 CTEPH is a particular form of PH linked to acute or chronic venous 
thromboembolism (VTE) and demands careful and specific clinical management since it 
is a potentially curable disease.19 Some other diseases can be accompanied of PH by 
unclear and/or multifactorial mechanisms (group 5).  
 4 
The last update of the clinical and hemodynamic PH classification was proposed 
in the World Symposium of Nice, in 2015 (Tables 1 and 2) and integrates the current 
guidelines for PH diagnosis and treatment.8,10  
 
 
Table 1. Clinical classification of pulmonary hypertension, as updated from Simonneau et 
al.20  
1. Pulmonary arterial 
hypertension 
2. Pulmonary hypertension due 
to left heart disease 
4. Chronic thromboembolic 
pulmonary hypertension and other 
pulmonary artery obstructions 1.1 Idiopathic  
1.2 Heritable 
   1.2.1 BMPR2 mutation 
   1.2.2 Other mutations 
1.3 Drugs and toxins induced  
1.4 Associated with: 
   1.4.1 Connective tissue disease 
   1.4.2 Human immunodeficiency                    
         virus (HIV) infection 
   1.4.3 Portal hypertension 
   1.4.4 Congenital heart disease 
   1.4.5 Schistosomiasis 
2.1 Left ventricular systolic  
      dysfunction 
2.2 Left ventricular diastolic   
      dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart  
      inflow/outflow tract  
obstruction and congenital     
      cardiomyopathies 
2.5 Congenital/acquired  
      pulmonary veins stenosis 
4.1 Chronic thromboembolic  
      pulmonary hypertension  
4.2 Other pulmonary artery  
      obstructions 
4.2.1 Angiosarcoma 
4.2.2 Other intravascular tumors 
4.2.3 Arteritis 
4.2.4 Congenital pulmonary arteries  
         stenosis  
4.2.5 Parasites (hydatidosis) 
1’. Pulmonary veno-occlusive 
disease and/or pulmonary 
capillary hemangiomatosis 
3. Pulmonary hypertension due 
to lung diseases and/or hypoxia 
5. Pulmonary hypertension with 
unclear and/or multifactorial 
mechanisms 
1’.1 Idiopathic  
1’.2 Heritable 
    1’.2.1 EIF2AK4 mutation 
    1’.2.2 Other mutations 
1’.3 Drugs, toxins and radiation  
        induced  
1’.4 Associated with: 
    1’.4.1 Connective tissue   
              disease  
     1’.4.2 HIV infection 
3.1 Chronic obstructive  
      pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases  
      with mixed restrictive and 
       obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation  
      disorders 
3.6 Chronic exposure to high  
      altitude 
3.7 Developmental lung diseases 
5.1 Hematological disorders: chronic  
      hemolytic anemia,  
      myeloproliferative disorders,  
      splenectomy 
5.2 Systemic disorders: sarcoidosis,  
      pulmonary histiocytosis,  
      lymphangioleiomyomatosis,  
      neurofibromatosis 
5.3 Metabolic disorders: glycogen  
      storage disease, Gaucher disease,  
      thyroid disorders 
5.4 Others: pulmonary tumoral  
      thrombotic microangiopathy,  
      fibrosing mediastinitis, chronic  
      renal failure (with/without  
      dialysis), segmental pulmonary  
      hypertension 
1”. Persistent pulmonary 
hypertension of the newborn 
 
BMPR2 = bone morphogenetic protein receptor, type 2; EIF2AK4 = eukaryotic translation initiation factor 2 alpha kinase 4; HIV = 
human immunodeficiency virus. Adapted from Galiè et al. Eur Respir J. 2015;46(4):903-975. 
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Table 2. Hemodynamic definitions of pulmonary hypertension. 
Definition Characteristics Clinical group(s) 
PH PAPm ≥25 mmHg All 
Pre-capillary PH PAPm ≥25 mmHg  
PAWP ≤15 mmHg 
1. Pulmonary arterial hypertension 
3. PH due to lung diseases 
4. Chronic thromboembolic PH 
5. PH with unclear and/or 
    multifactorial mechanisms 
Post-capillary PH 
 
 
Isolated post-capillary PH  
(Ipc-PH) 
         
Combined post-capillary and pre-capillary PH 
              (Cpc-PH) 
PAPm ≥25 mmHg  
PAWP >15 mmHg 
 
DPG <7 mmHg and/or  
PVR ≤3 WU 
 
DPG ≥7 mmHg and/or  
PVR >3 WU 
2. PH due to left heart disease  
5. PH with unclear and/or 
    multifactorial mechanisms 
CO: cardiac output; DPG: diastolic pressure gradient (diastolic PAP – mean PAWP); mPAP: mean pulmonary arterial pressure; 
PAWP: pulmonary arterial wedge pressure; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; WU: Wood units. 
Adapted from Galiè et al. Eur Respir J. 2015;46(4):903-975. 
 
 
Classifying PH patients according to the PH clinical classification is of major 
importance to define a clinical management strategy, namely in terms of drug selection 
(Table 3). Only group 1 forms of PH (PAH) and some group 4 (CTEPH) patients have 
indication for treatment with specific pulmonary vasodilators and/or specific 
interventional or surgical treatments (pulmonary balloon angioplasty, pulmonary 
endarterectomy or lung transplantation). 
 
 
Table 3. Treatment approaches according to PH etiology. 
PH etiology Treatment  
Group 1 
Endothelin receptor antagonists (ERA), phosphodiesterase type 5 inhibitors (PDE5i), 
guanylate cyclase stimulators (sGC), prostacyclin analogues and prostacyclin receptor agonists 
Group 2 Diuretics, beta-blockers, angiotensin-converting enzyme inhibitors (ACEi) 
Group 3 Oxygen, bronchodilators (BDL), noninvasive ventilation (NIV) 
Group 4 Pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), riociguat 
Group 5 Unknown 
 
 
Group 1 and group 4 forms of PH have a low incidence (2.4-7.6 and 5 cases per 
million, respectively) and prevalence (15-52 and 38.4 cases per million, respectively)21,22 
and are considered rare diseases, requiring a special healthcare organization, centered 
in dedicated referral centers.8,10,23,24  
A precise etiologic diagnosis is crucial for the determination of patient prognosis 
and for establishing the best treatment approach. The diagnostic algorithm 
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recommended by the guidelines defines very well the steps and tools to get a precise 
etiology. A considerable number of invasive and non-invasive tests are recommended; 
their correct technical execution and clinical interpretation are determinant of the results. 
This is the reason why most of them should be done in specialized centers with a high 
volume of tests to provide the experience to get the best information from them. This 
complexity of the diagnostic work-up also requires specialized organization to get the 
best results. Multidisciplinary discussion between experienced experts in PH to integrate 
test results with the clinical picture should also be routinely done in the clinical 
management of PH. 
Current treatment of PAH, mainly medical treatment with specific pulmonary 
vasodilator drugs, has improved patients prognosis and survival dramatically, from a 
median survival of 2.8 years25 in the 1980s to around 9 years nowadays.26 These results 
have evolved progressively during the past two decades thanks to a better understanding 
of PAH pathophysiology and identification of three main pathways implicated in the onset 
and progression of the disease—endothelin, nitric oxide, and prostacyclin pathways—
thus representing meaningful targets for therapeutic interventions.14 Numerous targeted 
PAH drugs were developed and approved (bosentan, ambrisentan, macitentan, 
sildenafil, tadalafil, riociguat, epoprostenol, iloprost, treprostinil, beraprost and selexipag) 
and used as monotherapy or in combination therapy.27–30 Furthermore, a trend emerged 
in clinical trials design in PAH from short-term, scarce endpoints (e.g. WHO FC, 6MWD, 
hemodynamic parameters and others) evaluation towards long-term outcome studies 
using composite morbidity and mortality endpoints.31,32   
Recent cohort studies and meta-analysis indicate that aggressive treatment 
strategies with early combination therapies are associated with improved 
outcomes.27,28,33,34 These outcomes depend mainly on the definition of a correct 
treatment strategy that includes: (1) continuous patient risk of 1-year mortality 
assessment; (2) best use of drugs according to risk stratification (monotherapy or 
combination therapy, and this last one as sequential add-on or as upfront combination 
of drugs); and (3) pursuing objectives, trying to bring and keep the patient in the low risk 
of 1-year mortality zone .35–39 PAH and CTEPH patient’s clinical management in a referral 
center, and the availability and accessibility to medical and surgical treatments, are other 
important determinants of outcomes.40,41  
 
1.1.2. Healthcare organization in Pulmonary Hypertension 
 
The rare condition of PAH and CTEPH coupled with the complex work-up 
diagnostic approach and difficult treatment decisions, as well as the high costs 
associated with their clinical management 42,43 lead to a consensus among stakeholders 
towards the implementation of country or multinational networks based in referral 
centers.23,24 Most European countries have their national networks for rare diseases and, 
recently, the European Reference Network (ERN) for rare and low prevalence complex 
diseases, including PH, was implemented by the European Commission.44  Today it is 
unquestionable that national networks for rare diseases improve disease management, 
including disease awareness, early referral to expert centers, diagnosis, and facilitate 
access to recommended treatments. As a natural consequence, patients achieve better 
outcomes in terms of functionality, quality of life, and survival. Furthermore, this type of 
organization can provide data for healthcare planning and cost control.  
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Regional networks, such as ERN, allow for mutual consultancy between centers 
as well as cross-border care. This kind of organization provide the patients served by the 
network access to the most sophisticated care. The concentration of a high number of 
patients in referral centres also allows highly specialized centers to gain high-volume-
based knowledge and experience in rare procedures (balloon septostomy, 
bronchopulmonary angioplasty, pulmonary endarterectomy and lung transplantation), 
which improves the quality of care and optimizes resources utilization with the respective 
cost savings.45–48 
 
1.1.3. Information systems in Pulmonary Hypertension 
 
A dedicated healthcare organization for rare diseases should be supported by 
specific electronic systems, which ideally should integrate and communicate with other 
electronic data-generating systems.49 Modern information technologies provide the 
possibility to design dedicated software able to help and educate PH teams and to 
support investigators in their clinical and research activities. Real-world databases for 
research can be built while performing routine daily clinical activities. Flexible and 
dynamic systems, giving the possibility of personal customization, can be offered to 
users according to their needs and wishes. Common electronic Case Report Forms 
(eCRF) can be designed for clinical studies. Current cloud hosting technology makes it 
easy to build big data banks for research.50  
Demographic, clinical and biobank data can be combined for research in the field 
and to advance towards personalized medicine.51 Information retrieved from this type of 
electronic support can help in developing knowledge about PH epidemiology (i.e. 
registries), patient characterization (phenotypes and genotypes), and outcomes, as well 
as improving quality and financial management by healthcare providers and authorities. 
Real-world clinical studies based on structured data coming from daily practices are also 
of uppermost importance for the development and approval of innovative therapies.52 
PH registries conducted to date were an important source of information and 
contributed for great advances in the knowledge of epidemiology, clinical characteristics, 
interventions and outcomes of this population. Still, some weaknesses and difficulties 
can be found53: most registries are not representative of real-world patient population 
because of selection bias; missing data is also a common issue and most of them are 
not true prospective studies; furthermore, the data collection methodology usually 
implies double record of patient data, which, in addition to the added work and resources 
consumption, further contributes to selection bias and missing data. 
Therefore, improved dedicated electronic tools are needed. They should be 
specifically designed to be user friendly and actually help PH teams in their clinical and 
research activities; they should be flexible, dynamic and customizable, in order to 
generate eCRFs, with mandatory fields, in a way that provides structured data for 
automatic reports and data analysis. Additionally, the integration/communication with 
other electronic systems generating health data is of paramount importance for a better 
understanding of these groups of diseases and for the improvement of healthcare quality 
and outcomes, as well as planning and regulation.54  
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1.1.4. Quality of life and disability in Pulmonary Hypertension 
 
According to the WHO’s concept of health—"A state of complete physical, mental, 
and social well-being not merely the absence of disease"—, patient evaluation should 
be extended over the physical aspects (e.g. clinical measures, biomarkers and others) 
and include Quality of Life (QoL) and/or Health-related QoL evaluation (HRQoL).55 
Defining the concepts of health status, HRQoL, and QoL is yet a matter of 
controversy among experts, which is well expressed in the medical literature.56 Health 
status is defined as the narrower of the three concepts, including all aspects of physical, 
mental, and social functioning that characterize an individual at a given time. HRQoL, on 
the other hand, evaluates the effects of the physical, mental, and social aspects, and 
particularly the effects of illness and treatment, on the individual’s sense of well-being. 
QoL is the broader of the three concepts covering all aspects of life, including non-health-
related aspects such as economic status, social participation, and others, to characterize 
an individual’s overall sense of well-being. Specifically, the WHO defines QoL as “an 
individual's perception of his position in life in the context of the culture and value systems 
in which he lives and in relation to his goals, expectations, standards and concerns. It is 
a broad ranging concept affected in a complex way by the person's physical health, 
psychological state, personal beliefs, social relationships and their relationship to salient 
features of his environment”.55 
Recommendations from the 4th and 5th World Symposium on PH reinforce the 
importance of measuring patient-reported outcomes (PRO) as a secondary end-point in 
clinical trials.57,58 These developments reflect the rising importance attributed to the 
patient voice in the drug development and approval process across therapeutic areas.59 
Importantly, the US Food and Drug Administration (FDA) has implemented a Patient-
Focused Drug Development (PFDD) initiative, intended to bring patient perspectives into 
the early stages of product development.60 After conducting a public meeting to capture 
patients’ perspectives about their disease and its impact on their daily life, the FDA has 
established guidance providing clear scientific standards for clinical outcome 
assessment in PAH,61 defining a patient-reported outcome measure (PROM) as a report 
of the status of a patient’s health condition that comes directly from the patient, without 
interpretation of the patient’s response by a clinician or anyone else.62 
Numerous PROMs for the assessment of QoL/HRQoL are available for the general 
population, but few have been validated for PH. Most of them are used in multiple 
diseases and are called general PROMs. CAMPHOR is the only PROM specifically 
created and validated to assess HRQoL and QoL in PH (i.e. PH-specific PROM). All 
these instruments are difficult to apply because of their extension, they have a large 
number of questions, which makes them very time-consuming and most of them require 
interpretation by a clinician. Thus, simpler and easier to use questionnaires, some of 
them already approved by regulatory agencies, such as emPHasis-10 63,64 and 
Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®),65,66 have 
been proposed and are under evaluation, including for use in clinical trials.67 
The use of PROMs is a very important component in evaluating the global health 
state of patients and a fundamental piece towards patient-centered, patient-engaged, 
and self-managed medicine.  
 In addition to HRQoL/QoL evaluation, it is also very important in the management 
of PH patients to define and evaluate functionality/disability given the highly debilitating 
nature of these groups of diseases. The WHO also developed the International 
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Classification of Functioning, Disability and Health (ICF), which provides an integrative 
approach to evaluate the level of health and disability at both individual and population 
levels.68 ICF is operationalized through the WHO Disability Assessment Schedule 
(WHODAS 2.0),69 which is an instrument for assessing health status and disability across 
different populations and settings, while providing a more accurate basis for comparisons 
between diseases. 
 
1.2. Thesis Structure 
 
The proper management of a rare and highly debilitating disease such as 
Pulmonary Arterial Hypertension requires a centralized healthcare organization system, 
facilitated access to accurate and vast clinical and nonclinical patients’ data on an 
electronic repository, and the availability of tools able to capture patient-reported 
outcomes and other forms of patient assessment. The work reported in this Thesis aimed 
to contribute to fill some of the gaps in PH management in Portugal. 
 
This Thesis is organized in five chapters.  
 
In Chapter I, the author describes pulmonary hypertension and the complexities 
associated to its management. Furthermore, areas requiring research and development 
are identified, constituting the scientific background for the research conducted by the 
author and his associates. 
 
In Chapter II the author presents the organizational context in which his research 
has been developed, and for which he has played an active role, namely in the definition 
and implementation of the PH healthcare organization in Portugal and the development 
of a PH-specific information system (PAH ToolTM) for use in PH management and clinical 
research.  
 
Taking advantage of the favorable operational conditions characterized in Chapter 
II, the following investigational projects were planned and implemented, and their results 
are presented in Chapters III and IV, in the form of reprints from papers published by 
peer-reviewed scientific journals:  
 
- To study the epidemiology, clinical characteristics and outcomes of Pulmonary 
Hypertension (PH) in Portugal (Chapter III), this chapter reports: 
• Data from a nationwide PH Registry. 
• Real-world data from a PH expert referral center. 
• Long-term survival data from a PH expert referral center.  
 
- To study the QoL, HRQoL and Disability impairment in Pulmonary Arterial 
Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) 
populations (Chapter IV), this chapter reports: 
• Validation of a specific-PH QoL questionnaire (the CAMPHOR) for the 
Portuguese population. 
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• Results from the application of a PH-specific QoL questionnaire 
(CAMPHOR) and a general HRQoL questionnaire (NHP) to PAH and 
CTEPH populations. 
• Disability assessment in PAH and CTEPH populations using the 
WHODAS 2.0 questionnaire. 
 
In the last chapter (Chapter V), the author discusses what has been achieved and 
the prospects for future developments in PH management and draws his conclusions on 
the work done. 
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2. CHAPTER II – Pulmonary Hypertension 
healthcare organization 
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2.1. Centralized healthcare management system for Pulmonary 
Hypertension 
 
PH encompasses a significant number of diseases, some of them rare, complex 
and life-threatening.20 The low number of patients makes it difficult for them to have 
significant capacity for intervention with healthcare authorities and the society in general. 
As in most rare diseases, PAH and CTEPH require complex clinical management and 
treatment with high-cost drugs, that, if not adequately managed by the healthcare 
system, constitute a substantial financial burden for healthcare providers (e.g., 
hospitals), which can be a motive for resistance in accepting these patients. Taken 
together, all these facts lead to the recommendation for concentration of patients in 
highly specialized centers and the allocation of adequate financial resources.23,24,43,70–72 
In the last 20 years, patients’ and professionals’ associations, healthcare providers 
organizations and pharmaceutical companies, have been working towards increasing 
awareness among healthcare authorities for the need of a dedicated healthcare 
organization with a dedicated budget in the field of PH. 
The European Commission launched, in 2008, a special program to alert European 
countries for the need to find better healthcare organizations for the management of Rare 
Diseases.71 These directives were followed by Council Recommendations that called on 
Member States to put national strategies in place72 and for strengthening the balance in 
the pharmaceutical systems in the EU and its Member States.70  
In Portugal, in 2008, during the national discussion process for the implementation 
of the directives from the European Commission for Rare Diseases, a project for PH 
healthcare organization was presented by the Study Group of Pulmonary Vascular 
Diseases of the Portuguese Internal Medicine Society and was accepted by the General-
Directorate of Health (Direção Geral de Saúde, DGS). A Technical Commission, 
integrated in the Quality Department of DGS, was created to implement it.73 The author 
of this thesis was nominated as coordinator of this Technical Commission. 
The project (organization chart in Figure 1) was implemented: the 1st Portuguese 
Guidelines for PH were published,74 applications for referral centers were opened,75 and 
a dedicated information system was provided to the authorities to help on the regulation 
of clinical practices and costs. 
Four referral centers fulfilled the required criteria and were nominated as official 
centers for the treatment of PH,75  and a dedicated reimbursement budget was created 
for these centers. The Unidade de Doença Vascular Pulmonar do Centro Hospitalar do 
Porto, led by the author of this thesis, was one of the four appointed PH referral centers. 
A first national Registry was launched, to provide epidemiologic data to characterize the 
Portuguese PH population and served as a basis for healthcare planning.76 
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Figure 1. PH Portuguese Organization Chart. 
 
The proposed organization was based on the experience from similar systems 
already implemented in other European countries, the best examples of which were the 
French and British systems.24,77 The longstanding and tight relationship with the 
organizers of the French network was of foremost importance for the success of the 
initiative. Their continuous support, being present in numerous national and regional 
scientific meetings, where political discussion with authorities was fomented, was crucial 
to support the project. In addition, their support to meet care needs not existent in the 
Portuguese Network (Surgical treatment of PH: endarterectomy and lung 
transplantation), putting in place at the time a true cross-border healthcare, were and are 
invaluable contributes for the care of Portuguese PH patients. 
 
 
2.2. Integration of the Unidade de Doença Vascular Pulmonar do Centro 
Hospitalar do Porto in the European Reference Network for rare and low 
prevalence complex diseases 
 
The European Reference Networks (ERNs), created under the “Directive 
2011/24/EU on patients’ rights in cross-border healthcare”78, were implemented to 
improve patient access to highly-specialized, high-quality, and safe care, pooling 
knowledge and improving diagnosis and care in medical fields where expertise is rare.  
In 2017, the European Commission launched the ERN for rare and low prevalence 
complex diseases program. Twenty-four ERNs were created being the ERN-LUNG, 
dedicated to Rare Respiratory Diseases, one of them. The ERN-LUNG (https://ern-
lung.eu) encompasses 9 groups of respiratory rare diseases, including the Pulmonary 
Hypertension group constituted by 17 Centers (illustrated in Figure 2). The sole 
Portuguese center belonging to ERN-LUNG is Unidade de Doença Vascular Pulmonar 
Directorate-General of Health 
Quality & Innovation Department / Technical Commission for PAH
Guidelines
Referral 
centers
Clinical 
pathways
Information 
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Registry Regulation
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do Centro Hospitalar do Porto, which is led by the author of this thesis, after a very 
demanding but successful application. 
ERN-LUNG is defined as “a non-profit, international, professional, patient-centric 
and scientific network and it is committed Europe-wide and globally to the prevention, 
diagnosis and treatment of rare respiratory diseases through patient care and advocacy, 
education and research”. Integrating this network will surely have great benefits for 
Portuguese patients (access to all available therapies through cross-border care), 
professionals (consultancy, training and shared research projects), and healthcare 
providers (healthcare and organizational quality improvements as a result of benchmark 
and audits).   
 
 
Figure 2. PAH centers in the European Reference Network for rare and low prevalence 
complex diseases. Source: https://ern-lung.eu, accessed on August 28th, 2018. 
 
  
• NUMBER OF CENTRES: 17
• NAME OF THE CENTRES: 
• NUMBER OF PATIENTS IN THE CN > 5,000
8
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2.3. PAHTool™: An information technology tool for patient’s management 
and clinical research in Pulmonary Hypertension 
 
Modern information technologies have been revolutionizing access to information 
and the way we organize society.79 Medicine, as a scientific discipline that is highly 
dependent on research and circulation of information, has benefited largely from the 
progresses in electronic access to information. Electronic technologies, with their great 
capacity of storage and high-speed access to data, provide new opportunities for the 
development of large and robust databases for clinical and investigational purposes. 
Modern computing technology allows the design of friendly and helpful systems to assist 
healthcare teams in their daily clinical practice. Telemetry and wearable technology allow 
the incorporation of in- or out-patient information introduced by the patient himself or 
collected from external portable devices (wearables).67,80 Electronic Health Records 
(EHR) incorporating all these data can provide a huge amount of information, covering 
all aspects of the health state of the individual, and be a huge source of information for 
both healthcare and research. Cloud services give us the possibility to have universal 
systems and big data banks81,82 at the distance of a click on the keyboard of a computer 
or a mobile device. Incorporation of artificial intelligence and machine learning in medical 
decision processes will assist the exercise of medicine in the future.83–86 Such 
technological advances will allow the implementation of real-world clinical trials and 
registries in the near future.87 Ultimately, advanced EHRs, which incorporate 
social/behavioral measures linked with biobanks and vital records collected from 
wearable devices, will greatly improve our understanding of disease, clinical care 
approaches, and overall public health.80–82  
Due to its rare nature and complexity, PH requires highly specialized care in 
referral centers, which should be supported by dedicated information systems helping 
PH teams in their daily activities while storing real-world clinical information to provide 
databases for the evaluation of clinical activities, clinical research, and healthcare 
planning and regulation. To our knowledge, before the development of Pulmonary 
Arterial Hypertension tool (PAHTool™), there was no dedicated electronic information 
system for PH addressing all these objectives.  
PAHTool™ (http://www.pahtool.net) was created by the author of this Thesis and 
a software company (Inovultus, Lda, Santa Maria da Feira, Portugal), in 2008. 
PAHTool™ is a software for PH disease management and clinical research and 
incorporates the most recent recommendations for clinical management of PH; these 
recommendations are organized in a wizard composed of specific pages (illustrated in 
Figure 3): identification, clinical classification, previous and current history, tests and 
treatments. This wizard is flexible and dynamic (fields can be visible or hidden, 
mandatory or not and new fields can be added) and customizable according to the user 
needs; a specific eCRF can be designed for each user project (center, national or 
international registry, clinical trial or other) and different eCRFs can coexist linked to the 
project name. “Clinical picture” (a summary of patient’s demographic, clinical 
characteristics and treatments) and “Follow-up tables and graphics” (fast and easy way 
to evaluate patient evolution, including risk assessment, and make treatment decisions) 
are innovative implementations and extremely useful guides for fast and easy clinical 
decisions. Automatic generated tests and clinical reports are useful helpers for PH 
teams, saving their time and allowing them to send information to other information 
systems or to other healthcare providers. A section with patient “Synthesis” (discharge, 
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referral, lost to follow-up or death) provides information for clinical, administrative and 
outcomes analysis. All stored data are automatically exportable to an excel sheet or to 
other data analysis software, as a global export or in a “tailored” fashion (structured 
queries: user chooses filters and parameters to export). Pre-defined searches present 
automatically generated tables and graphics giving the user administrative (e.g. number 
of patients, visits, hospitalization types, others), demographic (age, gender), 
epidemiological (incidence, prevalence, time to diagnosis), clinical (presentation signs 
and symptoms, etiology, clinical evolution of main parameters, treatments), and 
outcomes (mortality and survival) information. 
Figure 3. Information flow generated by PAHTool™. 
Integration of 2015 ESC/ERS guidelines clinical classification linked to the various 
nosology classifications (e.g. ICD, ORDO, OMIM, MeDRA, UMLS) make it possible to 
stratify patients in homogeneous sub-groups and to have robust information about true 
epidemiology, different demographic and phenotype/genotypic characteristics, as well 
as of outcomes according to different interventions. In addition, real-world structured 
information for research (e.g. clinical trials, registries, others) is permanently available 
without duplicating the user work.   
PAHTool™ was tested in the UDVP of CHP, and later made available to other 
Portuguese centers and to the Portuguese authorities. It was hosted in a server of the 
General-Directorate of Health and made available as a cloud service to the official PH 
Portuguese centers. A national database was built powered by individual centers’ data, 
which remained the “owners” of their data. Each center has an administrator that defines 
the user profile of their collaborators and participates in the decisions for studies sharing 
data. Some joint collaboration studies were produced and published76 as well as single 
center studies, including all the papers of this thesis.88–92 
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In 2013, the French PH network leaders of the very well-known French national 
registry decided to move from their old tool to PAHTool™. A joint collaboration project 
was launched. PAHTool™ was reformulated according to the French network needs and 
migration of around 8,000 patients was done at the time. Since then PAHTool™ is the 
national platform for this very important PH registry and its database has been the source 
for the numerous publications of this highly active group.93,94 
Other countries (13) and centers (69) adopted PAHTool™, which is now spread all over 
the World (Figure 4), serving at the moment 7 national Registries and including more 
than 20,000 PH patients.  
 
Figure 4. Countries using PAHTool™. 
Source: http://www.pahtool.net/Customers.html, accessed on August 28th, 2018. 
 
During the last 5 years numerous meetings were organized with PH experts and 
scientific PH organizations over the world, contributing to the improvement of the project 
and of the tool. An International registry of centers/countries using PAHTool™, with a 
common eCRF to answer specific questions: demographics, etiologies, patient 
phenotypes and presentation (risk assessment), prescribed drugs and treatment 
strategies as well as outcomes, is being discussed by the international group of 
PAHTool™ users.  
 
The organizational achievements presented above facilitated the implementation 
of the investigational projects that will be described in the next chapters 
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PAH is a rare condition that is not yet fully characterized. Over the years, several 
international registries and cohort studies contributed to establish the epidemiology and 
natural course of the disease in its various forms. But with the introduction of targeted 
disease-specific therapy it became increasingly important to assess patients’ clinical 
characteristics and disease course in order to achieve the best possible patient 
outcomes and contribute to a better knowledge of epidemiology that could inform 
healthcare planning.   
 
We conducted a prospective, observational, and multicenter registry with a joint 
collaboration from five centers around Portugal: “Pulmonary Hypertension in Portugal: 
1st Data from a Nationwide Registry”,76 published in BioMed Research International 
(2013). This registry provided the first systematic data on the clinical characteristics and 
management of the PH population in Portugal. The overall incidence for PAH (1.5 to 2.2 
patients per million) and CETPH (1.1 patients per million) was similar to that reported in 
other registries and cohort studies. Most (74.0%) patients were in WHO functional class 
III or IV, showing that they were diagnosed late in the course of their disease. CHD-PAH 
(21.7%) was found to be a frequent etiology which may warrant special attention to these 
diseases surgical repair during infancy. The one-year survival estimates for this incident 
cohort exceeded 93.0% for both PAH and CTEPH groups, a value that reflected access 
to contemporary medical treatment for PAH; in contrast, only 10.8% of CTEPH patients 
were submitted to pulmonary endarterectomy, and no patient was submitted to lung 
transplantation, which reflects difficulties of access to surgical treatments for PH patients 
in Portugal.  
 
Later we conducted a long-term analysis (mean follow-up time of 3.82.7 years) of 
real-world data from a population of 101 patients with pre-capillary pulmonary 
hypertension, followed between 2002 and 2013 at a PH reference center in Porto, 
Portugal. “Pulmonary Hypertension: Real-world Data From a Portuguese Expert Referral 
Centre”, 91 was published in Pulmonology (2018). The most frequent etiologies found 
were CHD (36.3%) followed by I/HPAH (32.7%) and CTEPH (25.7%). At presentation, 
patients showed mostly intermediate or high risk of 1-year estimated mortality (>60%), 
which could be indicative of delay in diagnosis and highlights the need to increase 
awareness among clinicians and promote early referral to expert centers. Most patients 
were treated with PAH-specific therapy (91.1%), as monotherapy (42.6%), double 
(29.7%) or triple (18.8%) combination therapy. During the course of the study, 42.3% of 
CTEPH patients underwent PEA. There was a significant improvement of WHO FC 
(p<0.003), mean 6MWD (p=0.003), mPAP (p=0.002), and PVR (p=0.008) for the overall 
study population; no significant changes were observed in RAP and CI for either the 
overall population or sub-group analysis. During the follow-up period, a total of 28 
(27.7%) patients died of PH-related causes; their median survival time from diagnosis 
was 3.1 years and only 17.9% of them were under triple combination therapy. For the 
overall study cohort, 1-, 3-, and 5-year survival was estimated at 86.6%, 76.7%, and 
64.1%, respectively. Survival was significantly better for patients 40 years old and 
women with I/HPAH. Survival estimates for the overall cohort and the PAH subgroup 
followed the trends of the most relevant international cohorts, while survival estimates 
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were lower than comparable studies for the CTEPH subgroup, which could be connected 
to difficulties in accessing PEA surgery. 
 
Given the importance of treatment innovations—new drugs and strategies—that 
occurred in recent decades, we conducted a study to compare treatment outcomes in 
different periods (2005-2010 vs. 2011-2016) in a PH reference center in Porto, Portugal. 
“Long-term Survival in Pulmonary Arterial Hypertension and Chronic Thromboembolic 
Pulmonary Hypertension: Insights From a Referral Centre in Portugal”,89 was published 
in Portuguese Journal of Cardiology (2018). In this study, involving 142 patients, 5-year 
survival estimates tended to improve over time for overall group 1 (67% vs 74%), mainly 
for CTD-PAH (33 vs 67%) and for CTEPH patients (77% vs 84%), but not for I/HPAH (84 
vs 75%). Other relevant findings included: 1) at diagnosis most of the patients were in 
advanced WHO FC (62% in III/IV FC); 2) the mean age at diagnosis of I/HPAH patients 
increased over time (5418 vs 3915 years); 3) specific treatments used and survival 
estimates are comparable to other registries and cohort studies; and 4) PEA and lung 
transplantation were underused treatments despite being associated with better survival 
of CTEPH and PAH patients. To further improve prognosis, use of parenteral prostanoids 
and better access to surgical treatments (PEA and lung transplantation) need to be 
promoted. These results were highlighted in an editorial by Prof. Marc Humbert, which 
considered our data important to better perceive this rare disease in a time in which there 
are increasing efforts to better understand rare diseases in Europe, the reason why the 
European Commission launched the European Reference Networks for rare and low 
prevalence complex diseases. The contribute of the Portuguese PH research community 
developing a dedicated information system for PH was also emphasized in this 
editorial.94 
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Besides the traditional clinical indicators used in clinical practice and research, it is 
increasingly important to assess the actual impact of disease and treatments on patients’ 
lives. With such purpose, different measures of quality of life (QoL), health-related quality 
of life (HRQoL) and functionality/disability are available for use in clinical practice and 
research. Some outcome measures were developed for a specific disease context, while 
others are applicable to a broader population. 
 
CAMPHOR is a patient-reported outcome measure (PROM) specifically developed 
to assess QoL impairment in PH patients. We conducted the study “Portuguese 
Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) 
Questionnaire”,92 that was published in Health and Quality of Life Outcomes (2016). The 
Portuguese version showed good psychometric properties and was found to be valid and 
reliable, being therefore recommended for use. This was at the time the only disease-
specific PROM validated for the Portuguese PH population. 
 
Since PH is a highly debilitating condition with potentially relevant impact on quality 
of life, and there are numerous questionnaires to evaluate that impact, we conducted a 
study to assess the self-reported HRQoL of Portuguese PH patients using two 
questionnaires, one specifically designed for PH (CAMPHOR) and a general one (NHP).  
“Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A 
Cross-Sectional Study”,90 was published in BioMed Research International (2018). 
HRQoL showed to be impaired in Portuguese patients with PAH and other forms of pc-
PH, particularly in patients with increased disease severity. Both general (Nottingham 
Health Profile, NHP) and disease-specific instruments (CAMPHOR) showed comparable 
HRQoL impairment in this patient population. CAMPHOR also showed a moderate 
impairment in overall QoL. WHO FC, 6MWD, and Borg dyspnea index were highly 
correlated with HRQoL impairment in this cohort, as well as with QoL measured through 
CAMPHOR. Despite some limitations, namely in measuring mental status, CAMPHOR 
demonstrated to be a useful disease-specific instrument and it was, at the time, the only 
instrument designed for PH measuring of overall QoL. 
 
In addition to QoL, it is also of the upmost importance to assess the degree of 
disability that PH patients endure. Therefore, we conducted the study “Disability and Its 
Clinical Correlates in Pulmonary Hypertension Measured Through the World Health 
Organization Disability Assessment Schedule II (WHODAS 2.0): a Prospective, 
Observational Study”, accepted for publication in Jornal Brasileiro de Pneumologia. This 
study intended to evaluate the degree of disability of pre-capillary PH patients using 
WHODAS, an internationally recognized instrument for this purpose. Patients showed 
mild disability, which could be associated with the low to intermediate disease severity 
of the cohort. Higher degree of disability was found in the domains of Mobility and Life 
activities. The main clinical correlates of disability in this population were WHO functional 
class, fatigue, and dyspnea. WHODAS 2.0 scores at baseline predicted 6MWD and 
WHO functional class over an 11-month follow-up period. This study was the first to 
assess disability in PH using WHODAS 2.0, allowing a basis for comparison with other 
disease stages, one of the main goals of this WHO questionnaire. 
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5.1. Integrated discussion, clinical implications and prospects for future 
developments 
 
A national healthcare organization system for PH, in line with that of most 
European countries and according to European Commission recommendations for rare 
diseases, is being implemented in Portugal. Four referral centers for PH were designated 
by the national authorities, in 2013. One of these centers integrates the European 
Reference Network for rare and complex low prevalence diseases. These centers built 
regional reference networks for PH, covering all the country. A dedicated reimbursement 
budget for referral centers was approved and helped to break barriers for the acceptance 
of these highly costly patients by healthcare providers.   
However, some organizational gaps remain: there is not yet a regular program of 
pulmonary endarterectomy for CTEPH patients, neither a lung transplantation program 
for PAH patients not responding to medical therapy, and, most importantly, there is not 
yet a true commitment of health authorities to improve and regulate the organization 
achieved, namely implementing the obligation to register all patients by the official 
referral centers to provide data for planning (epidemiology) and regulation (good 
practices and costs).  
Although cross-border healthcare provided by some European reference centers 
helps to resolve part of the PH surgical treatment gap, most of the patients with indication 
for these types of surgery do not accept the risk of doing it abroad. It is time to improve 
access of these patients to these successful and cost-saving surgeries, nominating and 
supporting the training of one national center in those procedures. These political options 
are being discussed with national authorities, with the active involvement of the 
Portuguese PH patient’s association. 
 
Development and validation, by the national and international PH community, of a 
dedicated information system for PH (PAHTool™) was achieved. Continuous 
development of the system and customization for the users is now an obligation of its 
authors. Its integration in general EHR generating systems is a priority to make it ever 
easier to use in the daily practice of PH teams. Its continuous adaptation for real-world 
registries, clinical trials and other types of research is compelling and is under continuous 
development. Incorporation of patient-reported data (QoL/Disability questionnaires and 
data from wearable technologies) and connection with other databases (e.g. biobanks, 
biomarkers, and others) will help move towards precision/personalized medicine and will 
follow the recommendations to integrate patients’ perspectives in the early stages of drug 
development according with the FDA’s Patient-Focused Drug Development (PFDD) 
initiative. 
Future implementation of an international registry, involving all centers using 
PAHTool™, with a common eCRF and precise objectives will surely help to know better 
PH epidemiology, patient phenotypes and outcomes. 
The expected connection of PAHTool™ with the ERN warehouse of registries, 
currently in progress, will facilitate PH ERN centers data exports and will enrich this large 
database that is currently being built. 
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From a national registry and two cohort studies that assessed patient 
characteristics and clinical outcomes in Portuguese PH patients, several relevant 
findings emerged. Although PAH is historically associated with younger patients, there 
is a clear trend for aging populations in I/HPAH and CTD-PAH sub-groups. The classical 
female predominance continues to be seen in these studies. 
In the Portuguese population, CHD-associated PAH is highly prevalent, compared 
to what would be expected from international settings. On the other hand, PAH 
associated with drugs, toxins, HIV, and portal hypertension are less frequent than what 
would be expected. These findings are an alert to the need of improving early surgical 
repair of congenital heart diseases and the awareness for these missing etiologies. 
These issues are part of the Portuguese PH scientific community concerns and integrate 
their permanent campaigns about PH.     
Markers of disease progression tended to improve overtime with the introduction 
of innovative treatments. Survival improved over time mainly for patients with non-
I/HPAH etiologies. The availability of all PAH-specific drugs leads to improvements in 
patient outcomes, although prostanoids remain underused in etiologies beyond I/HPAH. 
Surgical treatments for PH are also underused in Portugal due to the lack of expertise in 
the national centers. 
Establishing pre-defined diagnosis/treatment/follow-up protocols is crucial to 
achieve better and more personalized patient care that leads to improved clinical 
outcomes and survival. Well-designed EHR with appropriate eCRFs can play an 
important role in providing data for epidemiological purposes, as well as to assess patient 
outcomes, which can ultimately be very useful in supporting the development of better 
policies. 
The current Portuguese organizational model, while requiring further improvement, 
had a significant impact in improving outcomes of PH patients. Therefore, this strategy 
should be maintained, with continued assessment of outcomes. Some improvements to 
the current model can be outlined, namely extending the use of early and aggressive 
treatment strategies to non-I/HPAH etiologies and increasing the access to PH surgical 
treatments (PEA and lung transplantation). 
 
Traditionally, HRQoL/QoL evaluation in PH was limited to clinical trials and was 
typically considered as a secondary endpoint. However, progressively, these 
assessments have been included in the routine evaluation of PH patients and in the 
future these patient-focused measures will probably be considered markers of disease 
severity comparable to the typically used clinical markers. 
We have witnessed substantial developments in the HRQoL/QoL questionnaires 
used in PH, with a move from general instruments (e.g. SF36, NHP, and others) towards 
specific instruments (CAMPHOR), and most recently to patient-centered specific-PH 
PROMs (PAH-SYMPACT and emPHasis-10). These PH PROMs were developed in line 
with the FDA’s PFDD initiative and EMA’s guidelines, which aim to include the patients’ 
perspective in the early stages of product/drug development and are also being used in 
routine clinical practice since they are easy to apply, time-saving compared to existent 
questionnaires, and they serve the patient-centered/patient-engaged/self-managed 
medicine perspective. 
We validated a specific-PH questionnaire (CAMPHOR) for the pre-capillary PH 
Portuguese-speaking population, and we compared it with a general instrument (NHP) 
showing that they had similar capacity to evaluate HRQoL. However, only CAMPHOR 
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was able to evaluate QoL, once it is the only one designed to specifically assess overall 
QoL in the PH population. However, it also has some limitations: it is difficult to apply 
(long, time-consuming, needs external interpretation) and it is not ideal to assess 
mental/emotional status. PAH-SYMPACT and emPHasys-10 can be valuable tools to 
assess PH patients given their patient-centered design and, thus, validation of both 
instruments for the Portuguese speaking population is already in course. 
 
The assessment of disability has not, historically, been subject of much study in 
the PH population. However, with the trend towards patient-centered/patient-
engaged/self-managed medicine this issue is becoming increasingly relevant. 
Additionally, disability evaluation is important for legal assessment of work ability and 
approval for government-sponsored Social Security or employer-sponsored medical 
disability benefits. Experience shows that most patients with PH experience difficulty in 
qualifying for medical disability status, specially the PAH patient, typically a young patient 
with relatively normal physical examination. Legal definitions of disability for PH patients 
are scarce, based on criteria for cardiopulmonary diseases and most of the times of 
subjective interpretation. So, it is of major importance to have specific and objective 
measures that can be used in this group of patients. The ICF schedule and, specifically, 
WHODAS can facilitate the uniformization of criteria to define the degree of disability in 
a more objective manner. We assessed the degree of disability in a Portuguese 
population using WHODAS 2.0 and found that disability is really associated with disease 
severity as established by other clinical markers. These findings suggest that WHODAS 
2.0 could be a valuable tool to objectively establish the degree of patient disability in PH. 
More studies with larger Portuguese PH population samples are needed and are being 
planned. 
 
 
5.2. Conclusions  
 
For the first time, a nationwide registry was implemented in Portugal providing data 
for better understanding of the characteristics of the Portuguese PH population and for 
healthcare planning. A delayed diagnosis and absence of some etiologies were the most 
remarkable differences when compared with other national registries. A greater 
commitment of the PH clinical community and national authorities is needed to improve 
PH public awareness and early referral to the officially designated referral PH centers.  
 
Two real-world data publications from a Portuguese expert referral center showed 
patient characteristics and outcomes, including survival, similar to other referral centers 
or international registries. 
 
Patient-centered health outcomes are especially important for the management of 
diseases that have a marked negative impact in quality of life, as it is the case of PH. A 
PH-specific QoL questionnaire (CAMPHOR) was translated and successfully validated 
for use in the European Portuguese-speaking population and is now available for use in 
clinical routine and research activities.   
 
Health-related QoL may be significantly impaired in patients with PH. Both 
CAMPHOR, a PH-specific questionnaire, and NHP, a general questionnaire, showed to 
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adequately assess HRQoL. However, only CAMPHOR showed to capture QoL 
impairment. 
 
WHO ICF and WHODAS 2.0 questionnaire are valuable tools for the assessment 
of patients’ disability. We tested WHODAS 2.0 questionnaire for the first time in a PH 
population and it showed that the degree of disability is well correlated with disease 
severity. Further studies should be conducted to fully characterize the clinical value of 
ICF and WHODAS in PH, which is a highly disabling disease. 
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